Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

119.44
Delayed Data
As of 4:01pm ET
 +0.31 / +0.26%
Today’s Change
81.79
Today|||52-Week Range
126.07
+16.28%
Year-to-Date
JNJ Regular Dividend: JNJ began trading ex-dividend on 08/19/16. A $0.80 dividend will be paid to shareholders of record as of 08/23/16.
U.S. Stocks Trading Lower with Market Uncertainty
Aug 22 / GuruFocus News - Paid Partner Content
J&J: Don't Overpay for Lukewarm Results
Aug 19 / TheStreet.com - Paid Partner Content
Johnson & Johnson Could Become the First Company to Reach a $1 Trillion Valuation
Aug 22 / MotleyFool.com - Paid Partner Content
Is It "Game Over" After Portola's FDA Rejection?
Aug 18 / MotleyFool.com - Paid Partner Content
3 Stocks on the Rise You Can Buy Today
Aug 21 / MotleyFool.com - Paid Partner Content
Why I Hate Johnson & Johnson Right Now (But I'll Never Sell)
Aug 18 / MotleyFool.com - Paid Partner Content
Here's the Best Dividend Stock in Big Pharma
Aug 21 / MotleyFool.com - Paid Partner Content
Why Portola Pharmaceuticals Inc Is Plunging Today
Aug 18 / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: Cisco, Home Depot, Wal-Mart Beat, Berkshire Raises Stake in App...
Aug 19 / Zacks.com - Paid Partner Content
J&J (JNJ) Remicade Patent Invalid, Pfizer to Launch Inflectra?
Aug 18 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close119.13
Today’s open119.69
Day’s range119.02 - 119.96
Volume5,603,177
Average volume (3 months)6,928,527
Market cap$325.9B
Dividend yield2.68%
Data as of 4:01pm ET, 08/23/2016

Growth & Valuation

Earnings growth (last year)-3.86%
Earnings growth (this year)+7.83%
Earnings growth (next 5 years)+6.30%
Revenue growth (last year)-5.56%
P/E ratio22.2
Price/Sales4.12
Price/Book4.61

Competitors

 Today’s
change
Today’s
% change
PFEPfizer+0.25+0.72%
NVSNovartis+0.04+0.05%
AGNPRAAllergan plc-0.24-0.03%
MRKMerck+0.03+0.05%
Data as of 4:02pm ET, 08/23/2016

Financials

Next reporting dateOctober 11, 2016
EPS forecast (this quarter)$1.65
Annual revenue (last year)$70.2B
Annual profit (last year)$15.4B
Net profit margin21.95%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman &
Chief Executive Officer
Alex Gorsky
Chief Financial Officer &
Vice President
Dominic J. Caruso
Corporate headquarters
New Brunswick, New Jersey

Forecasts

Partner Offers

Search for Jobs